These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 18600596

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE, van Raalte DH, Diamant M.
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [Abstract] [Full Text] [Related]

  • 24. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH.
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
    Vilsbøll T, Holst JJ, Knop FK.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
    [Abstract] [Full Text] [Related]

  • 29. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH, Demuth HU, Pospisilik JA, Pederson R.
    Regul Pept; 2005 Jun 15; 128(2):159-65. PubMed ID: 15780435
    [Abstract] [Full Text] [Related]

  • 30. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA.
    Horm Metab Res; 2004 Jun 15; 36(11-12):852-8. PubMed ID: 15655719
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Incretin hormones and beta cell function in chronic pancreatitis.
    Knop FK.
    Dan Med Bull; 2010 Jul 15; 57(7):B4163. PubMed ID: 20591345
    [Abstract] [Full Text] [Related]

  • 35. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May 15; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
    Mudaliar S, Henry RR.
    Am J Med; 2010 Mar 15; 123(3 Suppl):S19-27. PubMed ID: 20206728
    [Abstract] [Full Text] [Related]

  • 40. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S, Collier A, Elhadd T, Malik I.
    J Indian Med Assoc; 2008 Jun 15; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.